Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | FAAH | O00519 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 5/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16373709 | 0.89 | RAB9A (1.00) | RAB9ASMN1; SMN2KMT2AMAPK1FAAH | |
| SCHEMBL16373634 | 0.87 | RAB9A (0.64) | RAB9ASMN1; SMN2KMT2AMAPK1FAAH | |
| SCHEMBL17511299 | 0.85 | SMN1; SMN2 (0.79) | RAB9ASMN1; SMN2KMT2AMAPK1FAAH | |
| SCHEMBL1178252 | 0.85 | RAB9A (0.71) | RAB9ASMN1; SMN2KMT2AMAPK1NPC1 | |
| SCHEMBL17511281 | 0.84 | RAB9A (0.70) | RAB9ASMN1; SMN2KMT2AMAPK1FAAH | |
| SCHEMBL1474047 | 0.84 | RAB9A (0.64) | RAB9ASMN1; SMN2KMT2AMAPK1NPC1 | |
| SCHEMBL16486106 | 0.83 | FAAH (0.95) | RAB9ASMN1; SMN2KMT2AMAPK1FAAH | |
| SCHEMBL3636405 | 0.81 | GSK3B (0.60) | RAB9ASMN1; SMN2KMT2AMAPK1FAAH | |
| SCHEMBL1474935 | 0.81 | FAAH (0.81) | RAB9ASMN1; SMN2KMT2AMAPK1FAAH | |
| SCHEMBL15190439 | 0.81 | RAB9A (0.57) | RAB9ASMN1; SMN2KMT2AMAPK1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | RAB9A 2013/4885SMN1; SMN2 3980/4885KMT2A 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.